His research is focused on androgen action in prostate cancer and benign prostatic hyperplasia. The Wang lab is actively pursuing following research directions: (a) the roles of androgen-responsive genes in prostate carcinogenesis, particularly the mechanisms of tumor suppression by ELL-associated factor 2 (EAF2), which is encoded by up-regulated androgen-responsive gene U19, (b) improvement of intermittent androgen deprivation therapy of prostate cancer based on differential action of testosterone and dihydrotestosterone (DHT), (c) the mechanisms regulating androgen receptor (AR) intracellular trafficking, level and activity, and (d) developing novel small molecule inhibitors targeting AR signaling for the treatment of prostate cancer that are resistant to current anti-androgens
Research Interests
Program
Molecular Pharmacology
Cellular and Molecular Pathology